ArticleHeart (British Cardiac Society)2022
Risk and predictors of heart failure in sarcoidosis in a population-based cohort study from Sweden.
Article in Heart (British Cardiac Society), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Sarcoidosis data-driven patient trajectories and predictors of chronic disease.Respiratory research · 2026Article
- The inflammatory fingerprint reveals immune cell populations associated with disease activity in cardiac sarcoidosis.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Increased Mortality and Morbidity in Patients With Heart Failure With Sarcoidosis Compared With Other Causes: A Propensity-Matched Nationwide Cohort Study.Journal of the American Heart Association · 2025Article
- Sarcoidosis in first- and second-generation immigrants: a cohort study of all adults 18 years of age and older in Sweden.International health · 2025Article
- Contemporary Diagnostics of Cardiac Sarcoidosis: The Importance of Multimodality Imaging.Diagnostics (Basel, Switzerland) · 2024Review
- Menopausal hormone therapy and risk of sarcoidosis: a population-based nested case-control study in Sweden.European journal of epidemiology · 2024Article
- Impact of comorbid heart failure among hospitalized patients with sarcoidosis: A United States population-based cohort study.International journal of cardiology. Heart & vasculature · 2023Article
- Incidence of Atrial Fibrillation as the Initial Manifestation of Cardiac Sarcoidosis: Insights From a Catheter Ablation Registry.CJC open · 2023Article
- Risk of out-of-hospital cardiac arrest in patients with sarcoidosis: a Danish nationwide nested case-control study.Open heart · 2023Article
- What Strain Analysis Adds to Diagnosis and Prognosis in Heart Failure Patients.Journal of clinical medicine · 2023Review
- Safety of corticosteroid therapy in sarcoidosis treatment.Frontiers in drug safety and regulation · 2023Review
- Comorbidities of sarcoidosis.Annals of medicine · 2022Review
- Association between sarcoidosis and cardiovascular Outcomes: A systematic review and Meta-analysis.International journal of cardiology. Heart & vasculature · 2022Article
- Epidemiology, Pathogenesis, and Diagnosis of Cardiac Sarcoidosis.Methodist DeBakey cardiovascular journal · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPrevious studies showed a strong association between sarcoidosis and heart failure (HF) but did not consider risk stratification or risk factors to identify useful aetiological insights. We estimated overall and stratified HRs and identified risk factors for HF in sarcoidosis.
methodsSarcoidosis cases were identified from the Swedish National Patient Register (NPR; ≥2 International Classification of Diseases-coded visits, 2003-2013) and matched to general population comparators. They were followed for HF in the NPR. Treated were cases who were dispensed ≥1 immunosuppressant ±3 months from the first sarcoidosis visit (2006-2013). Using Cox models, we estimated HRs adjusted for demographics and comorbidity and identified independent risk factors of HF together with their attributable fractions (AFs).
resultsDuring follow-up, 204 of 8574 sarcoidosis cases and 721 of 84 192 comparators were diagnosed with HF (rate 2.2 vs 0.7/1000 person-years, respectively). The HR associated with sarcoidosis was 2.43 (95% CI 2.06 to 2.86) and did not vary by age, sex or treatment status. It was higher during the first 2 years after diagnosis (HR 3.7 vs 1.9) and in individuals without a history of ischaemic heart disease (IHD; HR 2.7 vs 1.7). Diabetes, atrial fibrillation and other arrhythmias were the strongest independent clinical predictors of HF (HR 2.5 each, 2-year AF 20%, 16% and 12%, respectively).
conclusionsAlthough low, the HF rate was more than twofold increased in sarcoidosis compared with the general population, particularly right after diagnosis. IHD history cannot solely explain these risks, whereas ventricular arrhythmias indicating cardiac sarcoidosis appear to be a strong predictor of HF in sarcoidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.